Track BioNexus Gene Lab Corp Common stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioNexus Gene Lab Corp Common stock BGLC · Stock Open BioNexus Gene Lab Corp Common stock in new tab

1.20 USD
EPS
-1.26
P/B
0.40
ROE
-33.66
Beta
2.21
Loading chart...
Key Metrics
Earnings dateApril 21, 2026
EPS-1.26
Book Value3.22
Price to Book0.40
Debt/Equity4.16
% Insiders44.721%
Growth
Revenue Growth-0.97%

DCF Valuation

Tweak assumptions to recompute fair value for BioNexus Gene Lab Corp Common stock (BGLC)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

BioNexus Gene Lab Corp Common stock Logo BioNexus Gene Lab Corp Common stock Analysis (BGLC)

Malaysia Health Care Official Website Stock

Is BioNexus Gene Lab Corp Common stock a good investment? BioNexus Gene Lab Corp Common stock (BGLC) is currently trading at 1.20 USD.

Earnings Schedule: BioNexus Gene Lab Corp Common stock is expected to release its next earnings report on April 21, 2026.

Investor FAQ

Does BioNexus Gene Lab Corp Common stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioNexus Gene Lab Corp Common stock?

BioNexus Gene Lab Corp Common stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 21, 2026. The company currently has a trailing EPS of -1.26.

Company Profile

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Exchange Ticker
NMS (United States) BGLC
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 7, 2025 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion